Evidence map›Paper›PMID 41718957›Full record

ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2026

Functional mapping identifies early arrhythmogenic substrate in recurrent atrial fibrillation.

Chiara Valeriano, David Soto-Iglesias, Diego Penela, Giulio Falasconi, Dario Turturiello, Federico Landra, Jose Alderete, Daniel Viveros, Aldo Bellido, Fatima Zaraket and 15 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Chiara ValerianoCardiovascular Department, IRCCS Humanitas Research Hospital, Milan, Italy.
David Soto-IglesiasTeknon Medical Center, Heart Institute, Barcelona, Spain.
Diego PenelaCardiovascular Department, IRCCS Humanitas Research Hospital, Milan, Italy.
Giulio FalasconiTeknon Medical Center, Heart Institute, Barcelona, Spain.
Dario TurturielloTeknon Medical Center, Heart Institute, Barcelona, Spain.
Federico LandraTeknon Medical Center, Heart Institute, Barcelona, Spain.
Jose AldereteTeknon Medical Center, Heart Institute, Barcelona, Spain.
Daniel ViverosTeknon Medical Center, Heart Institute, Barcelona, Spain.
Aldo BellidoTeknon Medical Center, Heart Institute, Barcelona, Spain.
Fatima ZaraketTeknon Medical Center, Heart Institute, Barcelona, Spain.
Paula FrancoTeknon Medical Center, Heart Institute, Barcelona, Spain.
Carlo GiganteTeknon Medical Center, Heart Institute, Barcelona, Spain.
Lucio TeresiTeknon Medical Center, Heart Institute, Barcelona, Spain.
Bruno TonelloTeknon Medical Center, Heart Institute, Barcelona, Spain.
Lautaro Sánchez-MolláTeknon Medical Center, Heart Institute, Barcelona, Spain.
Alessia Chiara LatiniCardiovascular Department, IRCCS Humanitas Research Hospital, Milan, Italy.
Roberta MeaTeknon Medical Center, Heart Institute, Barcelona, Spain.
Carmine De LuciaTeknon Medical Center, Heart Institute, Barcelona, Spain.
Emanuele CurtiTeknon Medical Center, Heart Institute, Barcelona, Spain.
Andrea SagliettoDepartment of Medical Sciences, University of Turin, Turin, Italy.
Pietro FranciaCardiology, Department of Clinical and Molecular Medicine, St. Andrea Hospital, Sapienza University, Rome, Italy.
Etel Silva GarciaDepartment of Cardiology, Hospital Universitario Puerta del Mar, Cádiz, Spain.
Julio Martí-AlmorTeknon Medical Center, Heart Institute, Barcelona, Spain.
Juan Fernández-ArmentaDepartment of Cardiology, Hospital Universitario Puerta del Mar, Cádiz, Spain.
Antonio BerruezoTeknon Medical Center, Heart Institute, Barcelona, Spain. antonio.berruezo@quironsalud.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPulmonary vein isolation (PVI) often fails to prevent atrial fibrillation (AF) recurrence, particularly in persistent AF, where the atrial substrate plays a critical role. Endocardial scar reflects late and irreversible remodeling. Hidden slow conduction (HSC), unmasked by short-coupled extrastimuli, may represent an early functional marker of the arrhythmogenic substrate.

objectiveThis pilot study aimed to define the prevalence and distribution of HSC sites in recurrent AF and examine their relationship with structural remodeling markers, including low-voltage areas (LVAs), intramyocardial fat (inFAT), and left atrial wall thickness (LAWT).

methodsConsecutive AF patients (41% persistent, 59% paroxysmal) underwent multidetector CT with ADAS 3D LA™ segmentation of inFAT and LAWT, merged with left atrial voltage maps created using a contact-force ablation catheter. HSC sites were identified as fragmented or double electrograms evoked by triple extrastimuli.

resultsIn 22 consecutive patients, a total of 960 points were analyzed, with 14.5% testing HSC+. HSC+ sites clustered in the septum (34%) and anterior wall (14%). Compared with HSC– sites, they showed greater inFAT (dense: 79% vs. 40%; admixture: 89% vs. 67%; both p < 0.001) and lower voltage (0.80 vs. 1.13 mV, p < 0.001), but no significant association with LVAs or LAWT. AF duration (p = 0.004) and AF type (p = 0.018) were independent predictors of increased fat infiltration.

conclusionHSC+ sites cluster within fat-rich atrial regions, suggesting they may represent an early substrate component that promotes conduction slowing before the development of overt scar. Integrating HSC mapping with inFAT imaging may refine substrate characterization and guide targeted ablation strategies.

Indexed as

Atrial fibrillationFunctional substrateHidden slow conductionIntramyocardial fatLeft atrial wall thicknessMultidetector computed tomography

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.